Stock Track | GRAIL Shares Plummet 5.03% as Investors Digest Q1 Revenue Miss

Stock Track

May 16, 2025

GRAIL, Inc. (NASDAQ: GRAL), a healthcare company specializing in early cancer detection, saw its stock plummet 5.03% during Friday's intraday trading session. This decline appears to be a continued reaction to the company's disappointing first-quarter 2025 financial results released earlier in the week.

The sustained sell-off follows GRAIL's after-hours plunge of 14.90% on Tuesday when the company reported its Q1 earnings. Despite posting a narrower-than-expected loss of $3.10 per share, beating analyst estimates of a $3.99 per share loss, GRAIL's revenue fell short of expectations. The company reported revenue of $31.8 million, up from $26.7 million a year earlier, but significantly below the $35.2 million forecast by analysts.

While GRAIL highlighted some positive developments, including encouraging results from its NHS-Galleri trial and a strong cash position of $677.9 million providing runway into 2028, investors seem to remain focused on the revenue miss. As GRAIL continues to develop its multi-cancer early detection tests, the market appears to be reassessing the company's near-term growth prospects, leading to the ongoing pressure on its stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1108527984"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108527984\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108527984?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108527984","market":"sg","top_or_hot":-1,"title":"Stock Track | GRAIL Shares Plummet 5.03% as Investors Digest Q1 Revenue Miss","media":"Stock Track","content":"<p>GRAIL, Inc. (NASDAQ: GRAL), a healthcare company specializing in early cancer detection, saw its stock plummet 5.03% during Friday's intraday trading session. This decline appears to be a continued reaction to the company's disappointing first-quarter 2025 financial results released earlier in the week.</p>\n\n<p>The sustained sell-off follows GRAIL's after-hours plunge of 14.90% on Tuesday when the company reported its Q1 earnings. Despite posting a narrower-than-expected loss of $3.10 per share, beating analyst estimates of a $3.99 per share loss, GRAIL's revenue fell short of expectations. The company reported revenue of $31.8 million, up from $26.7 million a year earlier, but significantly below the $35.2 million forecast by analysts.</p>\n\n<p>While GRAIL highlighted some positive developments, including encouraging results from its NHS-Galleri trial and a strong cash position of $677.9 million providing runway into 2028, investors seem to remain focused on the revenue miss. As GRAIL continues to develop its multi-cancer early detection tests, the market appears to be reassessing the company's near-term growth prospects, leading to the ongoing pressure on its stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GRAIL Shares Plummet 5.03% as Investors Digest Q1 Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GRAIL Shares Plummet 5.03% as Investors Digest Q1 Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-16 23:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GRAIL, Inc. (NASDAQ: GRAL), a healthcare company specializing in early cancer detection, saw its stock plummet 5.03% during Friday's intraday trading session. This decline appears to be a continued reaction to the company's disappointing first-quarter 2025 financial results released earlier in the week.</p>\n\n<p>The sustained sell-off follows GRAIL's after-hours plunge of 14.90% on Tuesday when the company reported its Q1 earnings. Despite posting a narrower-than-expected loss of $3.10 per share, beating analyst estimates of a $3.99 per share loss, GRAIL's revenue fell short of expectations. The company reported revenue of $31.8 million, up from $26.7 million a year earlier, but significantly below the $35.2 million forecast by analysts.</p>\n\n<p>While GRAIL highlighted some positive developments, including encouraging results from its NHS-Galleri trial and a strong cash position of $677.9 million providing runway into 2028, investors seem to remain focused on the revenue miss. As GRAIL continues to develop its multi-cancer early detection tests, the market appears to be reassessing the company's near-term growth prospects, leading to the ongoing pressure on its stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"","article_id":"1108527984","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108527984","pubTimestamp":1747410861,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GRAIL, Inc. , a healthcare company specializing in early cancer detection, saw its stock plummet 5.03% during Friday's intraday trading session. This decline appears to be a continued reaction to the company's disappointing first-quarter 2025 financial results released earlier in the week.The sustained sell-off follows GRAIL's after-hours plunge of 14.90% on Tuesday when the company reported its Q1 earnings. Despite posting a narrower-than-expected loss of $3.10 per share, beating analyst estima","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc."},"translate_title":"由于投资者消化第一季度营收失误，GRAIL股价暴跌5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1},"content_text":"GRAIL, Inc. (NASDAQ: GRAL), a healthcare company specializing in early cancer detection, saw its stock plummet 5.03% during Friday's intraday trading session. This decline appears to be a continued reaction to the company's disappointing first-quarter 2025 financial results released earlier in the week.\nThe sustained sell-off follows GRAIL's after-hours plunge of 14.90% on Tuesday when the company reported its Q1 earnings. Despite posting a narrower-than-expected loss of $3.10 per share, beating analyst estimates of a $3.99 per share loss, GRAIL's revenue fell short of expectations. The company reported revenue of $31.8 million, up from $26.7 million a year earlier, but significantly below the $35.2 million forecast by analysts.\nWhile GRAIL highlighted some positive developments, including encouraging results from its NHS-Galleri trial and a strong cash position of $677.9 million providing runway into 2028, investors seem to remain focused on the revenue miss. As GRAIL continues to develop its multi-cancer early detection tests, the market appears to be reassessing the company's near-term growth prospects, leading to the ongoing pressure on its stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}